Source - LSE Non-Regulatory
RNS Number : 7917V
Braveheart Investment Group plc
16 December 2021
 

 

Reach - a non-regulatory announcement

 

 

16 December 2021

Braveheart Investment Group plc

("Braveheart" or the "Group")

Update re. PhaseFocus Holdings Limited

 

PhaseFocus has developed a series of patented computational imaging techniques that have a wide range of applications including live cell imaging, engineering metrology and electron microscopy. The research work and testimonials from the Francis Crick Institute, Huntsman Cancer Institute and universities of St Georges (London) and York give an insight to why Livecyte™ leads the market in cell imaging (https://phasefocus.com/resources/customer-testimonials).

 

Its distribution agreement with Swedish bio-convergence company BICO Group AB is now providing an excellent platform for driving sales growth across the EU and USA. BICO's CYTENA division is promoting Livecyte™ very strongly in its markets, https://www.cytena.com/livecyte/ with considerable success, and this month, PhaseFocus will ship three Livecyte™ cell imaging systems to CYTENA, destined for world leading research centres in the EU and USA. Demonstrations to public health laboratories by CYTENA are ongoing and the potential sales pipeline for 2022 is growing.

 

Following the recent sale of a Livecyte™ cell imaging system to St George's, University of London, PhaseFocus' UK distributor, Lablogic is targeting sales of Livecyte™ cell imaging systems to other UK's university-based researchers. A video of the Livecyte™ system working at St Georges University in London can be viewed here https://lablogic.com/life-sciences/instruments/phasefocus-livecyte.  

 

Additionally, PhaseFocus' distributors in China, Japan, Australia and Italy are also experiencing good levels of enquiry.

 

PhaseFocus is planning to expand its Nottingham production facility in Q1 2022 to meet this anticipated demand.

 

 

For further information: 



 

 

Braveheart Investment Group plc

Tel: 01738 587555

Viv Hallam, Executive Director

 

 

 

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

David Worlidge / James Hornigold

 

 

 

Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Heena Karani / Lucy Williams

 

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFFRFLLELIL
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.